Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 2, 2003, Pages 186-192

  Kankuri, Esko ^a   Hamalainen M ^b   Hukkanen, M ^b   Salmenpera P ^b   Kivilaakso, E ^b   Vapaatalo, H ^b   Moilanen, E ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

Anti inflammatory drugs; Inducible nitric oxide synthase; Nitric oxide; NOS inhibitors; Proinflammatory cytokines; Ulcerative colitis

Indexed keywords

3 NITROTYROSINE; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N ACETYL S NITROSOPENICILLAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; INCUBATION TIME; INFLAMMATION; INFLAMMATORY CELL; LAMINA PROPRIA; MALE; MUCOSA; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SAMPLING; ULCERATIVE COLITIS;

ADULT; AMIDINES; BENZYLAMINES; COLITIS, ULCERATIVE; COLON; CYTOKINES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; S-NITROSO-N-ACETYLPENICILLAMINE; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 0037299903     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000681     Document Type: Article

References (54)

1. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50.
2. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-9.
3. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
4. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314-25.
5. Hosokawa T, Kusugami K, Ina K, Ando T, Shinoda M, Imada A, et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999;14:987-96.
6. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-57.
7. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999;34:66-74.
8. Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk W, Gross V, et al. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 2000;46:350-8.
9. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9.
10. Godkin AJ, De Belder AJ, Villa L, Wong A, Beesley JE, Kane SP, et al. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 1996;26:867-72.
11. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615.
12. Kolios G, Rooney N, Murphy CT, Robertson DA, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. Gut 1998:43:56-63.
13. Salzman AL, Eaves-Pyles T, Linn SC, Denenberg AG, Szabo C. Bacterial induction of inducible nitric oxide synthase in cultured human intestinal epithelial cells. Gastroenterology 1998;114:93-102.
14. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-37.
15. Schmidt HHHW, Walter U. NO at work. Cell 1994;78:919-25.
16. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-16.
17. Fiorucci S, Distrutti E, Ajuebor MN, Mencarelli A, Mannucci R, Palazzetti B, et al. NO-mesalamine protects colonic epithelial cells against apoptotic damage induced by proinflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2001;281:G654-65.
18. Wallace JL, Vergnolle N, Muscara MN, Asfaha S, Chapman K, McKnight W, et al. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 1999;117:557-66.
19. Kankuri E, Asmawi MZ, Korpela R, Vapaatalo H, Moilanen E. Induction of iNOS in a rat model of acute colitis. Inflammation 1999;23:141-52.
20. Garvey EP, Oplinger JA. Furfine ES, Kiff RJ, Laszlo F, Whittle BJ, et al. 1400 W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997;272:4959-63.
21. Kankuri E, Vaali K, Knowles RG, Lähde M, Korpela R, Vapaatalo H, et al. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine. J Pharmacol Exp Ther 2001;298:1128-32.
22. Kiss J, Lamarque D, Delchier JC, Whittle BJ. Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 1997;336:219-24.
23. Menchen LA, Colon AL, Moro MA, Leza JC, Lizasoain I, Menchen P, et al. N-(3-(aminomethyl)benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Life Sci 2001;69:479-91.
24. Nakamura H, Tsukada H, Oya M, Onomura M, Saito T, Fukuda K, et al. Aminoguanidine has both an anti-inflammatory effect on experimental colitis and a proliferative effect on colonic mucosal cells. Scand J Gastroenterol 1999;34:1117-22.
25. Neilly PJ, Kirk SJ, Gardiner KR, Anderson NH, Rowlands BJ. Manipulation of the L-arginine-nitric oxide pathway in experimental colitis. Br J Surg 1995;82:1188-91.
26. Pfeiffer CJ, Qiu BS. Effects of chronic nitric oxide synthase inhibition on TNB-induced colitis in rats. J Pharm Pharmacol 1995;47:827-32.
27. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995;37:247-55.
28. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998;42:180-7.
29. Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996;111:871-85.
30. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 2001;41:203-36.
31. Broillet MC. S-nitrosylation of proteins. Cell Mol Life Sci 1999;55:1036-42.
32. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 1997;94:6954-8.
33. Marcinkiewicz J, Grabowska A, Chain B. Nitric oxide upregulates the release of inflammatory mediators by mouse macrophages. Eur J Immunol 1995;25:947-51.
34. Eigler A, Sinha B, Endres S. Nitric oxide-releasing agents enhance cytokine-induced tumor necrosis factor synthesis in human mononuclear cells. Biochem Biophys Res Commun 1993;196:494-501.
35. Lander HM, Sehajpal P, Levine DM, Novogrodsky A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol 1993;150:1509-16.
36. Van Dervort AL, Yan L, Madara PJ, Cobb JP, Wesley RA, Corriveau CC, et al. Nitric oxide regulates endotoxin-induced TNF-alpha production by human neutrophils. J Immunol 1994;152:4102-9.
37. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
38. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-440.
39. Bapat S, Verkleij A, Post JA. Peroxynitrite activates mitogen-activated protein kinase (MAPK) via a MEK-independent pathway: a role for protein kinase C. FEBS Lett 2001;499:21-6.
40. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-6.
41. Lander HM, Jacovina AT, Davis RJ, Tauras JM. Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J Biol Chem 1996;271:19705-9.
42. Foletta VC, Segal DH, Cohen DR. Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukoc Biol 1998;63:139-52.
43. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
44. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
45. Neurath MF, Fuss I, Schurmann G, Pettersson S, Arnold K, Muller-Lobeck H, et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann NY Acad Sci 1998;859:149-59.
46. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-69.
47. Felley-Bosco E, Ambs S, Lowenstein CJ, Keefer LK, Harris CC. Constitutive expression of inducible nitric oxide synthase in human bronchial epithelial cells induces c-los and stimulates the cGMP pathway. Am J Respir Cell Mol Biol 1994; 11: 159-64.
48. Gertzberg N, Clements R, Jaspers I, Ferro TJ, Neumann P, Flescher E, et al. Tumor necrosis factor-alpha-induced activating protein-1 activity is modulated by nitric oxide-mediated protein kinase G activation. Am J Respir Cell Mol Biol 2000;22:105-15.
49. Zhang Z, Kolls JK, Oliver P, Good D, Schwarzenberger PO, Joshi MS, et al. Activation of tumor necrosis factor-alphaconverting enzyme-mediated ectodomain shedding by nitric oxide. J Biol Chem 2000;275:15839-44.
50. Zhang Z, Oliver P, Lancaster JR, Jr, Schwarzenberger PO, Joshi MS, Cork J, et al. Reactive oxygen species mediate tumor necrosis factor alpha-converting enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 2001;15:303-5.
51. Kubes P. Inducible nitric oxide synthase: a little bit of good in all of us. Gut 2000;47:6-9.
52. McCafferty DM, Mudgett JS, Swain MG, Kubes P. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 1997;112:1022-7.
53. Roberts PJ, Riley GP, Morgan K, Miller R, Hunter JO, Middleton SJ. The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon. J Clin Pathol 2001;54:293-7.
54. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000;119:512-20.